| INTRODUCTION
Immune-checkpoint inhibitors have emerged as potent anti-cancer agents in a variety of tumours, including non-small-cell lung carcinomas (NSCLC). [1] [2] [3] [4] [5] [6] [7] With monoclonal antibodies against immune-checkpoint regulators: programmed cell death protein 1 (PD-1) receptor and its ligand, programmed death-ligand 1 (PD-L1), being recently approved as first-line treatment in advanced NSCLC, PD-L1 immunoassays performed on pathology specimens have emerged as predictive biomarkers for selecting patients for immunotherapy. 8, 9 For each PD-1/PD-L1 inhibitor therapy, a specific PD-L1 immunohistochemistry (IHC) assay has been developed with variable cut-off thresholds. 10 While most of these assays are complementary diagnostics, only 22C3 pharmDx (22C3) and SP263 assays (SP263) are companion diagnostics, essential for determining patient eligibility for pembrolizumab therapy. 10 Most studies on PD-L1 testing focus on histology samples, including small biopsies. [11] [12] [13] [14] NSCLC commonly presents in advanced inoperable stages, and cytology samples are frequently the only tumour material available for testing. 15, 16 Although a few studies have investigated the appropriateness of PD-L1 immunocytochemistry (ICC) in cytology specimens, most have evaluated cell blocks or direct smears only. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Cell blocks are frequently inadequate, while usage of direct smears may compromise archival material. We, in the present study, have analysed the feasibility of liquid-based cytology (LBC) smears for PD-L1 ICC using SP263 assay and compared with PD-L1 IHC performed on paired small biopsies in patients with NSCLC. 
| MATERIALS AND METHODS

| Case selection
| Processing of small biopsies
Samples were fixed in 10% neutral buffered formalin for at least 6 hours. Formalin-fixed paraffin-embedded (FFPE) sections were cut at 3-4-µm thickness, mounted on special coated slides, and IHC was performed within 15 days of sectioning.
| Cytology sample processing
Bronchial brushings and bronchial washings were processed by direct to slide BD SurePath ™ LBC (SurePath, Becton, Dickinson and company, Burlington, VT, USA) for nongynaecological specimens as per manufacturer's instructions. Bronchial brushing and washings were directly aspirated into 8-10 mL CytoRich Red®. The test tube was kept aside for 60 minutes to complete the fixation process and then centrifuged for 10 minutes at 450g to make a cell pellet.
The supernatant was decanted and 2-3 mL of distilled water was added to the pellet. BD pre-coated slides were placed inside the cassette and settling chamber was locked into position by rotating clockwise. One mL of BD density reagent and 1-2 mL of prepared sample were pipetted into settling chamber (which was fixed on the BD pre-coated slide) carefully, to maintain layer between density reagent and sample. The whole cassette assembly was centrifuged at 350g for 5 minutes. After removing the cassette assembly, the slide was washed and proceeded for Papanicolaou stain. 
| PD-L1 IHC/ICC
| Interpretation of PD-L1 staining
The entire slide was first scanned at ×4 objective magnification.
Well-preserved and well-stained areas of the specimen were selected effusions. In other studies, number of bronchial washes or brushings was very small. 25, 26 In most of the studies, 22C3 clone of antibody was used on Dako platform. 18, 19, 21, [23] [24] [25] [26] In clinical practice for Dako 22-C3
PharmDX assay, the tumour should be considered PD-L1 positive, and the patient is considered eligible for pembrolizumab as first-line therapy if the specimen shows high PD-L1 expression (tumour proportion score 50% or more), while at least 1%-49% PD-L1 expression is required for treatment in second-line or later. 10 Harmonisation between 22C3 and 28-8 pharmDx assay, and between company based and laboratory developed assay has also been achieved on cytology and histology samples. 18, 20, 21 In general, SP263 has been found out to be the best antibody to be harmonised and it has now been approved for pembrolizumab as a companion diagnostic assay. 10 We have used SP263 in matched biopsy and cytology samples due to inaccessibility of 22C3 clone and associated autostainer platforms. However, for durvalumab, less than 25% and 25% or more expression of SP263 has been decided to be important for clinicians. For nivolumab, less than 1%, 1% or more to less than 5%, 5% or more to less than 10%, and 10% or more cut-offs are recommended. Since in this study, we were not evaluating clinical response to any of these drugs and our aim was to see if PD-L1 expression can be determined on non-cell block cytology samples, we have decided to choose less than 25% and 25% or more expression. We did split our cases into less than 1%, 1% or more to less than 5%, 5% or more to less than 10%, and 10% or more. However, the number of cases in each category was small (less than 1%: 12 cases; 1% or more to less than 5%, one case; 5% or more to less than 10% or more: 12 cases) and insignificant. Therefore, to derive a meaningful score, we used less than 25% and 25% or more expression.
In contrast to other PD-L1 IHC assays where only membranous positivity is considered, SP263 staining is interpreted positive if membranous and/or cytoplasmic protein expression at any intensity greater than background staining is detected. 28 All but two studies have used CB for PD-L1 testing (Table 2) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Direct smears evaluated in one study showed stronger correlation with histology proportion scores than CB. 22 Our study is the first pilot effort to evaluate PD-L1 ICC on LBC specimens, especially using exfoliative samples, and has not been attempted previously to the best of our knowledge. Subsequent to success of LBC in cervical cytology, LBC of nongynaecological samples had been introduced for even distribution of cells, decreasing obscuring elements like blood and mucus in the background, better preservation of nuclear and cytoplasmic details and rapid fixation.
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In our study, we evaluated PD-L1 ICC on bronchial washings and brushing samples processed by LBC. This technique uses CytoRich
Red, which is a formalin and methanol-based fixative. PD-L1 ICC positivity was found in 9/12 PD-L1 positive biopsies yielding a sensitivity of 75% as compared to small biopsies. Three LBC smears were false negative, which may also be explained by a higher sampling bias in cytology samples further compounded by the known inherent heterogeneous tissue expression levels of PD-L1. One of these false negative LBC smears displayed aberrant nuclear expression of PD-L1, which was also reproduced on the corresponding alcohol fixed direct smear, and may be an effect of alcohol-based fixation. The SP263 assay is intended for laboratory use for the detection of the PD-L1 protein in FFPE tissue. 28 Although alcohol-based fixatives are not recommended for ICC, our placental touch preparations fixed in alcohol and CytoRich Red showed optimal cytoplasmic and membranous staining in syncytiotrophoblastic cells.
Several limitations of our study deserve detailed description.
First, we examined a small number of paired cases; therefore, our results may be affected by the small sample size. However; in practice, it was challenging to obtain matched cytology-histology samples with adequate number of tumour cells remaining in both following routine diagnosis and work-up. Second, we examined only LBC processed cytology samples and this study does not cover the heterogeneity of cytology preparations such as direct smears, and cell blocks. Although the paired direct smears included in our study showed a lower sensitivity for PD-L1 positivity (60%) as compared to LBC smears (75%), the very small number included may be a confounding factor. Third, we do not have clinical data on the responses to anti-PD-L1 immunotherapy. Our patients were not prospectively immunotherapy response data is required for further validating the usage of exfoliative cytology samples for PD-L1 testing and to assess if cytology specific cut-offs are required for determining patient eligibility for treatment.
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